WHO ICTRP trial
Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe…
ChiCTR2000032534 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000032534 |
|---|---|
| Public title | Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control study |
| Scientific title | Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control study |
| Primary sponsor | The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU. |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Rheumatoid arthritis |
| Interventions | Experimental group:Anbainuo plus methotrexate;Control group:Methotrexate, salazopyridine, leflumide, hydroxychloroquine |
| Registration date | May 1, 2020 |
| Target size | Experimental group:47;Control group:43 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: